Sanofi【SAN】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

90.62

買値

90.62

売値

90.63

出来高

89,352

90.40 日の範囲 90.94

83.28 52 週間の範囲 106.14

時価総額

113.514B

前日終値

90.80

始値

90.44

時刻

90.62

最終取引時間

17:42:40

財務取引量

VWAP

平均取引量 (3 か月)

1,551,907

発行済株式数

1,252,640,466

配当利回り

12.23%

PER

21.07

1 株当たり利益 (EPS)

4.31

歳入

43.07B

純利益

5.4B

セクター

Health & Allied Services,nec

業界

Pharmaceutical Preparations

ウェブサイト

www.sanofi.com

本社

Paris, Paris, Fra

設立

1994

Sanofi is listed in the Health & Allied Services sector of the ユーロネクスト with ticker SAN. The last closing price for Sanofi was 90.80 €. Over the last year, Sanofi shares have traded in a share price range of 83.28 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 113.74 € billion. Sanofi has a price to earnings ratio (PE ratio) of 21.07.

Sanofi: Information concerning the total number of voting rights and shares - October 2024

Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive...

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le...

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat...

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation...

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination...

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in the EU as the first and only medicine for young...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-2.74	-2.93487574979	93.36	94.4	90.17	1814250	91.84798828	DE
4	-7.79	-7.91586220913	98.41	101.9	90.17	1631654	95.74355537	DE
12	-10.02	-9.95627980922	100.64	106.14	90.17	1551907	100.27061623	DE
26	1.05	1.17226750028	89.57	106.14	85.94	1488487	96.10824111	DE
52	5.62	6.61176470588	85	106.14	83.28	1452003	92.81723408	DE
156	1.23	1.37599284036	89.39	106.66	76.45	1759780	92.49180759	DE
260	8.36	10.1628981279	82.26	106.66	67.65	1956228	89.3084835	DE

銘柄コード	株価	出来高
ATODSAtos SE	0.005 € (21.95%)	10.16M
SOISOITEC	73.35 € (15.51%)	110.33k
ALMDPMedesis Pharma SA	0.47 € (14.36%)	78.76k
HYLHyloris Pharmaceuticals SA	5.88 € (13.51%)	25.06k
ALINSIntrasense	0.314 € (12.54%)	116.27k
EBUSEbusco Holding NV	0.90 € (-26.59%)	708.66k
VACBSPierre & Vacances	0.048 € (-14.29%)	427
EMGDSEuromedis DS	0.0088 € (-12.00%)	2.65k
ALVETTheraVet SA	0.0802 € (-10.89%)	28.77k
ALESEEntech SA	4.85 € (-9.51%)	52.77k
ATODSAtos SE	0.005 € (21.95%)	10.16M
ALVERVergnet	0.0052 € (8.33%)	5.8M
ALTDTonner Drones	0.0098 € (6.52%)	3.78M
BCPBanco Comercial Portugues SA	0.4385 € (-0.30%)	2.21M
ATOAtos SE	0.181 € (-5.97%)	1.78M

銘柄コード

株価

出来高

ATODSAtos SE

0.005 €

(21.95%)

10.16M

ALVERVergnet

0.0052 €

(8.33%)

5.8M

ALTDTonner Drones

0.0098 €

(6.52%)

3.78M

BCPBanco Comercial Portugues SA

0.4385 €

(-0.30%)

2.21M

ATOAtos SE

0.181 €

(-5.97%)

1.78M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sanofi (SAN)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Sanofi について

SAN 最新ニュース

Sanofi: Information concerning the total number of voting rights and shares - October 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024

Sanofi: Information concerning the total number of voting rights and shares - October 2024

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sanofi (SAN) 銘柄情報

Sanofi (SAN)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Sanofi について

SAN 最新ニュース

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手